BACKGROUND AND OBJECTIVES: The prevalence of chronic kidney disease (CKD) has increased over the past two decades. The sensitivity of serum creatinine (sCr) to identify CKD is low. As a result, many healthcare centers report estimated GFR (eGFR) with routine blood work. The aim of this study was to determine the cost-effectiveness of automatic eGFR reporting compared with reporting sCr alone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A Markov model was designed to evaluate the cost-effectiveness of reporting eGFR compared with reporting sCr alone in a hypothetical cohort of 60-yr-old individuals undergoing annual blood chemistry testing over 18 yr. Paths and path probabilities were identical between the two arms, except for the sensitivity and specificity of eGFR and sCr to detect CKD. RESULTS: eGFR reporting was dominant with a cost/effectiveness ratio of $16,751/quality-adjusted life year (QALY) versus $16,779/QALY for sCr reporting. Monte Carlo microsimulations in a hypothetical cohort of 10,000 patients demonstrated that over 18 yr, an average of 13 fewer deaths, 29 fewer ESRD events, and 11,348 more false positive CKD (FP-CKD) cases occurred with eGFR reporting. A sensitivity analysis revealed that decreasing the FP-CKD quality of life by > 2% rendered sCr reporting more cost-effective than eGFR reporting. If FP-CKD reduced quality of life by 5%, the incremental cost-effectiveness ratio for sCr reporting versus eGFR reporting would be $4367/QALY. CONCLUSION: A decision analysis suggests that reporting eGFR may be beneficial, but this limited benefit was reversed with virtually any reduction in quality of life caused by incorrect diagnosis of CKD.
BACKGROUND AND OBJECTIVES: The prevalence of chronic kidney disease (CKD) has increased over the past two decades. The sensitivity of serum creatinine (sCr) to identify CKD is low. As a result, many healthcare centers report estimated GFR (eGFR) with routine blood work. The aim of this study was to determine the cost-effectiveness of automatic eGFR reporting compared with reporting sCr alone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A Markov model was designed to evaluate the cost-effectiveness of reporting eGFR compared with reporting sCr alone in a hypothetical cohort of 60-yr-old individuals undergoing annual blood chemistry testing over 18 yr. Paths and path probabilities were identical between the two arms, except for the sensitivity and specificity of eGFR and sCr to detect CKD. RESULTS: eGFR reporting was dominant with a cost/effectiveness ratio of $16,751/quality-adjusted life year (QALY) versus $16,779/QALY for sCr reporting. Monte Carlo microsimulations in a hypothetical cohort of 10,000 patients demonstrated that over 18 yr, an average of 13 fewer deaths, 29 fewer ESRD events, and 11,348 more false positive CKD (FP-CKD) cases occurred with eGFR reporting. A sensitivity analysis revealed that decreasing the FP-CKD quality of life by > 2% rendered sCr reporting more cost-effective than eGFR reporting. If FP-CKD reduced quality of life by 5%, the incremental cost-effectiveness ratio for sCr reporting versus eGFR reporting would be $4367/QALY. CONCLUSION: A decision analysis suggests that reporting eGFR may be beneficial, but this limited benefit was reversed with virtually any reduction in quality of life caused by incorrect diagnosis of CKD.
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey Journal: Ann Intern Med Date: 2001-07-17 Impact factor: 25.391
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: V Menon; X Wang; M J Sarnak; L H Hunsicker; M Madero; G J Beck; A J Collins; J W Kusek; A S Levey; T Greene Journal: Kidney Int Date: 2008-03-12 Impact factor: 10.612
Authors: Carmen A Peralta; Michael G Shlipak; Suzanne Judd; Mary Cushman; William McClellan; Neil A Zakai; Monika M Safford; Xiao Zhang; Paul Muntner; David Warnock Journal: JAMA Date: 2011-04-11 Impact factor: 56.272
Authors: Julie A Wright; Kenneth A Wallston; Tom A Elasy; T Alp Ikizler; Kerri L Cavanaugh Journal: Am J Kidney Dis Date: 2010-12-18 Impact factor: 8.860
Authors: Manjula Kurella Tamura; Shuchi Anand; Suying Li; Shu-Cheng Chen; Adam T Whaley-Connell; Lesley A Stevens; Keith C Norris Journal: Am J Kidney Dis Date: 2011-03 Impact factor: 8.860
Authors: Carmen A Peralta; Feng Lin; Michael G Shlipak; David Siscovick; Cora Lewis; David R Jacobs; Kirsten Bibbins-Domingo Journal: Nephrol Dial Transplant Date: 2010-06-02 Impact factor: 5.992
Authors: Carmen A Peralta; Ronit Katz; Mark J Sarnak; Joachim Ix; Linda F Fried; Ian De Boer; Walter Palmas; David Siscovick; Andrew S Levey; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 14.978
Authors: David H Smith; Jennifer Schneider; Micah L Thorp; Suma Vupputuri; Jessica W Weiss; Eric S Johnson; Adrianne Feldstein; Amanda F Petrik; Xuihai Yang; Susan R Snyder Journal: BMC Nephrol Date: 2012-11-23 Impact factor: 2.388